Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.67 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.67 |
| ▸ | SCD | O00767 | 5/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166992 | 0.94 | HCRTR2 (0.64) | HCRTR2HCRTR1SCDSCD5ALDH1A1 | |
| SCHEMBL1167151 | 0.92 | HCRTR2 (0.78) | HCRTR2HCRTR1 | |
| SCHEMBL1166921 | 0.91 | HCRTR2 (0.66) | HCRTR2HCRTR1SCDSCD5ALDH1A1 | |
| SCHEMBL1167173 | 0.91 | HCRTR2 (0.66) | HCRTR2HCRTR1SCDSCD5ALDH1A1 | |
| SCHEMBL1167000 | 0.90 | HCRTR2 (0.64) | HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL1166720 | 0.89 | HCRTR2 (0.63) | HCRTR2HCRTR1SCDSCD5ALDH1A1 | |
| SCHEMBL1167751 | 0.88 | HCRTR2 (0.66) | HCRTR2HCRTR1SCDSCD5ALDH1A1 | |
| SCHEMBL1166786 | 0.87 | HCRTR2 (0.62) | HCRTR2HCRTR1SCDSCD5ALDH1A1 | |
| SCHEMBL1166303 | 0.87 | HCRTR2 (0.63) | HCRTR2HCRTR1ALDH1A1LMNAHTT | |
| SCHEMBL1166423 | 0.87 | HCRTR2 (0.85) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | claimed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | HCRTR2 2700/4885HCRTR1 2862/4885SCD 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.